Synonyms:Levetiracetam, 102767-28-2, Keppra, (S)-2-(2-Oxopyrrolidin-1-yl)butanamide, Keppra XR, (2S)-2-(2-oxopyrrolidin-1-yl)butanamide, ucb L059, UCB-L 059, matever, UCB-L059, Levetiracetame, Levetiracetamum, Spritam, (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide, SIB-S1, Elepsia, Levetiracetam sun, (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide, Levetiracetam teva, UCB-22059, Levetiracetam accord, Levetiracetam [INN], Levetiracetam actavis, Levetiracetam hospira, UCB 22059, Levetiracetamum [INN-Latin], NSC-760119, 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-, CHEBI:6437, Levetiracetam In Sodium Chloride, AGB-101, N03AX14, 44YRR34555, Levroxa, (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide, Leviteracetam, Levipil, Torleva, Elepsia XR, (S)-Levetiracetam, SMR000466303, Keppra (TN), Levesam 500, Etiracetam levo-isomer, SR-01000759400, MFCD03265610, UNII-44YRR34555, E Keppra, HSDB 7528, Levetiracetam [USAN:USP:INN:BAN], E keppra (TN), Levetiracetam- Bio-X, (S)-2-(2-Oxo-1-pyrrolidinyl)butyramide, L-059, LEVETIRACETAM [MI], LEVETIRACETAM [JAN], CHEMBL1286, LEVETIRACETAM [HSDB], LEVETIRACETAM [USAN], LEVETIRACETAM [VANDF], 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (S)-, MLS000759403, MLS001424069, MLS006010215, BIDD:GT0242, LEVETIRACETAM [MART.], SCHEMBL118843, LEVETIRACETAM RATIOPHARM, LEVETIRACETAM [USP-RS], LEVETIRACETAM [WHO-DD], GTPL6826, Levetiracetam (JAN/USP/INN), DTXSID9023207, LEVETIRACETAM [EMA EPAR], LEVETIRACETAM ACTAVIS GROUP, Levetiracetam, >=98% (HPLC), Levetiracetam, analytical standard, HMS2051D07, HMS2089L20, HMS2235I18, HMS3262H11, HMS3713P16, HMS3884O11, Pharmakon1600-01502265, LEVETIRACETAM [EP IMPURITY], LEVETIRACETAM [ORANGE BOOK], ACT02712, ALBB-027275, BCP11856, HY-B0106, LEVETIRACETAM [EP MONOGRAPH], LEVETIRACETAM [USP IMPURITY], Tox21_500835, BDBM50422542, LEVETIRACETAM [USP MONOGRAPH], NSC760119, s1356, STL388027, Levetiracetam 1.0 mg/ml in Methanol, AKOS015841981, AC-1479, CCG-100928, CS-1854, DB01202, KS-1176, LP00835, NC00178, NSC 760119, SDCCGSBI-0633760.P001, (2S)-(2-Oxopyrrolidin-1-yl)butyramide, NCGC00186028-01, NCGC00186028-13, NCGC00261520-01, (S)-2-(2-oxopyrrolidin-1-yl)butyramide, BL164623, (s)-2-(2-oxopyrrolidin-1-yl) butyramide, AM20070676, L0234, SW197558-3, C07841, D00709, EN300-244575, AB00639945-06, AB00639945_07, AB00639945_08, A800616, (S)-2-(2-OXO-PYRROLIDIN-1-YL)-BUTYRAMIDE, Q-201292, SR-01000759400-4, SR-01000759400-5, (2S)-2-(2-oxopyrrolidin-1-yl)butanamide;Levetiracetam, Z1255435426, (-)-(S)-.ALPHA.-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE, 1-Pyrrolidineacetamide, .alpha.-ethyl-2-oxo-, (.alpha.S)-, Levetiracetam, European Pharmacopoeia (EP) Reference Standard, Levetiracetam, United States Pharmacopeia (USP) Reference Standard, (-)-(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide (2S)-2-(2-Oxo-pyrrolidin-1-yl)butanamide, Levitiracetam, Pharmaceutical Secondary Standard; Certified Reference Material
Pubchem:PUBCHEM:5284583
Id:de57e182-c14e-5d4f-8a01-af7fec2c782c
Description:nan
